UK AMD EMR USERS GROUP REPORT V : benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions..
BACKGROUND/AIMS: To study the effectiveness and clinical relevance of eyes treated with good (better than 6/12 or >70 Early Treatment Diabetic Retinopathy Study letters) visual acuity (VA) when initiating treatment with ranibizumab for neovascular age-related macular degeneration (nAMD) in the UK National Health Service. Currently eyes with VA better than (>) 6/12 are not routinely funded for therapy.
METHODS: Multicentre national nAMD database study on patients treated 3-5 years prior to the analysis. Anonymised structured data were collected from 14 centres. The primary outcome was the mean VA at year 1, 2 and 3. Secondary measures included the number of clinic visits and injections.
RESULTS: The study included 12 951 treatment-naive eyes of 11 135 patients receiving 92 976 ranibizumab treatment episodes. A total of 754 patients had baseline VA better than 6/12 and at least 1-year of follow up. Mean VA of first treated eyes with baseline VA>6/12 at year 1, 2, 3 were 6/10, 6/12, 6/15, respectively and those with baseline VA 6/12 to >6/24 were 6/15, 6/17, 6/20, respectively (p values <0.001 for comparing differences between 6/12 and 6/12-6/24 groups). For the second eyes with baseline VA>6/12, mean VA at year 1, 2, 3 were 6/9, 6/9, 6/10 and those with baseline VA 6/12 to >6/24 were 6/15, 6/15, 6/27, respectively (p values <0.001-0.005). There was no significant difference in the average number of clinic visits or injections between those with VA better and worse than 6/12.
CONCLUSIONS: All eyes with baseline VA>6/12 maintained better mean VA than the eyes with baseline VA 6/12 to >6/24 at all time points for at least 2 years. The significantly better visual outcome in patients who were treated with good baseline VA has implications on future policy regarding the treatment criteria for nAMD patients' funding.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
The British journal of ophthalmology - 99(2015), 8 vom: 01. Aug., Seite 1045-50 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Aaron Y [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.10.2015 Date Revised 09.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bjophthalmol-2014-306229 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM246226498 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM246226498 | ||
| 003 | DE-627 | ||
| 005 | 20231224142612.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bjophthalmol-2014-306229 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0820.xml |
| 035 | |a (DE-627)NLM246226498 | ||
| 035 | |a (NLM)25680619 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Aaron Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a UK AMD EMR USERS GROUP REPORT V |b benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12 |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.10.2015 | ||
| 500 | |a Date Revised 09.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. | ||
| 520 | |a BACKGROUND/AIMS: To study the effectiveness and clinical relevance of eyes treated with good (better than 6/12 or >70 Early Treatment Diabetic Retinopathy Study letters) visual acuity (VA) when initiating treatment with ranibizumab for neovascular age-related macular degeneration (nAMD) in the UK National Health Service. Currently eyes with VA better than (>) 6/12 are not routinely funded for therapy | ||
| 520 | |a METHODS: Multicentre national nAMD database study on patients treated 3-5 years prior to the analysis. Anonymised structured data were collected from 14 centres. The primary outcome was the mean VA at year 1, 2 and 3. Secondary measures included the number of clinic visits and injections | ||
| 520 | |a RESULTS: The study included 12 951 treatment-naive eyes of 11 135 patients receiving 92 976 ranibizumab treatment episodes. A total of 754 patients had baseline VA better than 6/12 and at least 1-year of follow up. Mean VA of first treated eyes with baseline VA>6/12 at year 1, 2, 3 were 6/10, 6/12, 6/15, respectively and those with baseline VA 6/12 to >6/24 were 6/15, 6/17, 6/20, respectively (p values <0.001 for comparing differences between 6/12 and 6/12-6/24 groups). For the second eyes with baseline VA>6/12, mean VA at year 1, 2, 3 were 6/9, 6/9, 6/10 and those with baseline VA 6/12 to >6/24 were 6/15, 6/15, 6/27, respectively (p values <0.001-0.005). There was no significant difference in the average number of clinic visits or injections between those with VA better and worse than 6/12 | ||
| 520 | |a CONCLUSIONS: All eyes with baseline VA>6/12 maintained better mean VA than the eyes with baseline VA 6/12 to >6/24 at all time points for at least 2 years. The significantly better visual outcome in patients who were treated with good baseline VA has implications on future policy regarding the treatment criteria for nAMD patients' funding | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Drugs | |
| 650 | 4 | |a Macula | |
| 650 | 4 | |a Retina | |
| 650 | 4 | |a Treatment Medical | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a VEGFA protein, human |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor A |2 NLM | |
| 650 | 7 | |a Ranibizumab |2 NLM | |
| 650 | 7 | |a ZL1R02VT79 |2 NLM | |
| 700 | 1 | |a Lee, Cecilia S |e verfasserin |4 aut | |
| 700 | 1 | |a Butt, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Xing, Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Robert L |e verfasserin |4 aut | |
| 700 | 1 | |a Chakravarthy, Usha |e verfasserin |4 aut | |
| 700 | 1 | |a Egan, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Akerele, Toks |e verfasserin |4 aut | |
| 700 | 1 | |a McKibbin, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Downey, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Natha, Salim |e verfasserin |4 aut | |
| 700 | 1 | |a Bailey, Clare |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Rehna |e verfasserin |4 aut | |
| 700 | 1 | |a Antcliff, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Varma, Atul |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Vineeth |e verfasserin |4 aut | |
| 700 | 1 | |a Tsaloumas, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Mandal, Kaveri |e verfasserin |4 aut | |
| 700 | 1 | |a Liew, Gerald |e verfasserin |4 aut | |
| 700 | 1 | |a Keane, Pearse A |e verfasserin |4 aut | |
| 700 | 1 | |a Sim, Dawn |e verfasserin |4 aut | |
| 700 | 1 | |a Bunce, Catey |e verfasserin |4 aut | |
| 700 | 1 | |a Tufail, Adnan |e verfasserin |4 aut | |
| 700 | 0 | |a UK AMD EMR Users Group |e verfasserin |4 aut | |
| 700 | 1 | |a Armstrong, Stewart |e investigator |4 oth | |
| 700 | 1 | |a Mohamed, Quresh |e investigator |4 oth | |
| 700 | 1 | |a Sallam, Ahmed |e investigator |4 oth | |
| 700 | 1 | |a Arora, Seema |e investigator |4 oth | |
| 700 | 1 | |a Cook, Helen |e investigator |4 oth | |
| 700 | 1 | |a Gopalakrishnan, Kala |e investigator |4 oth | |
| 700 | 1 | |a Lyon, Fiona |e investigator |4 oth | |
| 700 | 1 | |a Islam, Tahir |e investigator |4 oth | |
| 700 | 1 | |a Backhouse, Oliver |e investigator |4 oth | |
| 700 | 1 | |a Dabbs, Tim |e investigator |4 oth | |
| 700 | 1 | |a Davies, Bryn |e investigator |4 oth | |
| 700 | 1 | |a Mokete, Bataung |e investigator |4 oth | |
| 700 | 1 | |a Patel, Praveen J |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The British journal of ophthalmology |d 1917 |g 99(2015), 8 vom: 01. Aug., Seite 1045-50 |w (DE-627)NLM000087556 |x 1468-2079 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2015 |g number:8 |g day:01 |g month:08 |g pages:1045-50 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bjophthalmol-2014-306229 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2015 |e 8 |b 01 |c 08 |h 1045-50 | ||